MWNA
SLDB icon

Marshall Wace North America’s Solid Biosciences SLDB Stock Holding History

Marshall Wace North America’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$626K Sell
17,465
-80,080
-82% -$3.4M ﹤0.01% 1061
2021
Q2 		$5.36M Buy
97,545
+34,399
+54% +$2.27M 0.02% 532
2021
Q1 		$5.24M Buy
+63,146
New +$6.99M 0.02% 546
2018
Q2 		– Sell
-3,626
Closed -$408K – 1655
2018
Q1 		$408K Buy
+3,626
New +$1.22M ﹤0.01% 1196

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's SLDB Position: Q3 2021 in Review

Marshall Wace North America reduced its Solid Biosciences (SLDB) stake by 82% in Q3 2021, selling an estimated $3.4M and leaving 17,465 shares worth $626K. The position accounts for ﹤0.01% of the portfolio, ranked #1061.

Marshall Wace North America first reported a position in SLDB in Q1 2018 and has held it in 4 quarters since. The position peaked at $5.36M in Q2 2021. 91 funds tracked by Wall St. Rank hold SLDB as of Q3 2021.

  • Marshall Wace North America held 17,465 shares of Solid Biosciences worth $626K as of Q3 2021.
  • Marshall Wace North America sold 80,080 Solid Biosciences shares in Q3 2021, an estimated $3.4M.
  • Solid Biosciences made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1061 holding.
  • Marshall Wace North America first reported a position in Solid Biosciences in Q1 2018 and has held it in 4 quarters since.
  • Marshall Wace North America's Solid Biosciences position peaked at $5.36M in Q2 2021.
  • 91 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.